Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Thorac Oncol. 2021 Feb 3;16(5):850–859. doi: 10.1016/j.jtho.2021.01.1605

Figure 3. Genetic Alterations in Pre- and Post-Capmatinib Plasma Specimens.

Figure 3.

(A) Heatmap illustrates findings in pre-capmatinib and post-capmatinib plasma specimens from 10 patients with paired specimens. Colors in legend correspond to reason for discontinuing crizotinib (crizotinib row) and best response to capmatinib (capmatinib row). Gray box: not applicable (crizotinib and capmatinib rows). PD: disease progression; PR: partial response; SD: stable disease; tox: toxicity. (B) Molecular alterations detected in plasma from 13 patients relapsing on capmatinib. Each slice corresponds to a single patient. Amp: amplification; del: deletion; mut: mutation.